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correlated with downregulation and low cyclin E level (p=0.0003), and 
low Ki67 proliferative marker across histological types (p=0.005).
Conclusions: Our data provide the ﬁrst evident of a direct and func-
tional interconnection linking E2F1, the ratio of Skp2 / CUL1, and 
cyclin E oncoproteins in human tumors. Whereas Skp2 cooperate with 
E2F1 to activate its transcriptional function of E2F1 towards cyclin E, 
CUL1 was identiﬁed as a negative regulator of cyclin E suggesting that 
CUL1 could play a role in limiting the progression of neuroendocrine 
lung tumors. This indicates therapeutic target for inhibitors of protea-
some in high grade neuroendocrine lung tumors. 
D4-04 Pathology, Thu, 12:30 - 14:15
Useful prognostic factors in small-sized adenocarcinoma
Anami, Yoichi1 Suzuki, Kenji2 Matsuno, Yoshihiro3 Yokota, Jun4 
Noguchi, Masayuki1 
1 Dept. of Pathology, Graduate School of Comprehensive Human Sci-
ence, University of Tsukuba., Tsukuba, Japan 2 Division of Thoracic 
Surgery, National Cancer Center Hospital, Tokyo, Japan 3 Diagnostic 
Pathology Division, National Cancer Center Hospital, Tokyo, Japan 
4 Biology Division National Cancer Center Research Institute, Tokyo, 
Japan 
Background: With the progression of radiologic methodology such as 
thin section CT and/or high resolution CT, recently we become to diag-
nose many small-sized adenocarcinoma (less than 2 cm in diameter). In 
order to diagnose the degree of their malignancy, we need convenient 
prognostic factors. On the other hand, there are numerous prognostic 
factors reported those are useful to predict the prognosis of lung non-
small cell carcinoma and/or adenocarcinoma. However, the comparison 
among the factors has not been performed sufﬁciently, especially about 
small-sized early adenocarcinoma. This time, we selected 10 immuno-
histochemical prognostic factors reported before, such as CEA, p53, 
MIB1, p27, EGFR, pEGFR, Cox2, Neuromatin, γH2AX, and TTF-1 
and compared their conveniences using same series of small-sized 
adenocarcinomas. Furthermore, we also examined the ratio of bronchi-
oloalveolar cell carcinoma (BAC) component and micropapillary com-
ponent in maximum cut surface of the tumor as histologic factors and 
genome abnormalities of p53, K-ras, and EGFR were also examined. 
Methods: We conducted a retrospective review of 138 consecutive 
patients who underwent complete resection for small-sized adenocar-
cinoma and did not receive any chemotherapy and/or radiotherapy 
prior to surgery in National Cancer Center Hospital (Tokyo, Japan) 
from January 1993 to December 2000. We selected CEA, p53, MIB1, 
p27, EGFR, pEGFR, Cox2, Neuromatin, γH2AX and TTF-1 as im-
munohistochemial prognostic factors. In addition to the factors, we 
examined the ratio of BAC component and micropapillary component 
in maximum cut surface of the tumor using H.E. staining sections. 
Furthermore, p53, EGFR, and K-ras mutation analysis were performed 
on 78 cases. 
Results: Among the 10 immunohistochemical factors, two histological 
factors, and three genomic factors, CEA, MIB1 index, and BAC com-
ponent ratio were signiﬁcantly associated with the prognosis of small-
sized adenocarcinomas. Cases stained strongly with anti-CEA antibody 
showed signiﬁcantly less favorable prognosis than negative cases 
(p=0.02). Cases that revealed more than 10% of MIB1 index showed 
less favorable prognosis than cases less than 10% of the index. And 
cases with more than 50% of BAC component showed more favorable 
prognosis than cases with less than 50% of BAC component (p<0.01). 
However, the other factors were not related with the prognosis. 
Conclusion: Although numerous prognostic factors were reported about 
the lung adenocarcinoma, this study indicated that only three factors, 
namely, two immunohistochemical factors of CEA and MIB1 index and 
histological factor of the ratio of BAC component in the maximum cut 
surface of the tumor were signiﬁcantly associated with the prognosis of 
small-sized adenocarcinoma of the lung. In order to construct a desirable 
and evidence-based selective diagnosis of the cases for reduction sur-
gery, more extended study for searching convenient prognostic factors 
about small-sized adenocarcinoma should be performed.
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Atypical adenomatous hyperplasia (AAH) is a recognised precur-
sor for peripheral parenchymal-type adenocarcinoma whereby AAH 
transforms into localised non-mucinous bronchioloalveolar carcinoma, 
wherein alveolar collapse, stromal ﬁbrosis and invasion develop. In our 
patient population, AAH has been found in around 12% of lung cancer 
resections and in 23% of resections for adenocarcinoma. About half re-
ported AAH lesions are solitary, some cases yield between 2-5 lesions 
but up to 20% show over 5 lesions.
Little is known about the likelihood or rate of transformation of AAH 
into adenocarcinoma. The few follow-up studies published have involved 
relatively short follow-up and none have shown any relationship between 
AAH and survival. We present the ﬁrst case-control study investigating 
the survival of patients with AAH in lung resection specimens.
Methods: 116 patients with AAH in their resection specimen were 
compared with 232 controls without AAH. Cases and controls were 
matched for tumour histology, T & N stage, age and year of surgery. All 
cases were treated in the Aberdeen Cardio-Thoracic Surgery Unit, the 
tertiary specialist referral centre for the north of Scotland. All cases of 
AAH were detected during routine gross and histological examination 
of lungs resected for primary carcinoma. All lesions identiﬁed on gross 
examination of 1cm thick parasagittal slices of formalin-inﬂated lung 
resections were sampled and/or up to 6 random parenchymal tissue 
blocks were taken. Survival data were derived from our lung cancer 
resection database, Cancer Registry and Hospital patient data sources.
Results: Tumour stage, nodal status and histology (WHO 2004) were 
100% matched between cases and controls. Median ages were 65.4 
(IQR 57.5 - 71.0) and 64.5 (58.3 - 70.2) years respectively for cases 
and controls. More AAH patients were female (50.9% vs 35.3%, 
p=0.005). Of those cases with AAH, 15% had more than 5 lesions 
recorded. As expected, most (69%) of the cases had adenocarcinomas. 
Median follow-up was 32 months for cases and 30 months for controls 
(95th centiles 130 and 147 months respectively). 
No difference was found in the survival of cases with AAH and 
controls (Median survival [95% conﬁdence interval], 35 [12.3 - 57.7] 
months vs 39 [29.0 - 49.0] months respectively, p=0.81). When cases 
were categorised to identify patients with more than 5 AAH lesions 
(n=17), median survivals for cases with 1-5 AAH lesions was 36 
[11.9 - 60] months while for those with over 5 AAHs it was 22 [0 
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- 57] months, however this difference was not statistically signiﬁcant 
(p=0.56). In multi-variate analysis, T and N status (p<0.001), large cell 
undifferentiated and sarcomatoid histology (p=0.045 and 0.050) and 
female gender (p=0.029) were signiﬁcantly associated with survival 
but there was no evidence of interactions between the presence of AAH 
and any of these factors. 
Conclusion: In this case-control study the presence of AAH in lungs 
resected for primary carcinoma does not inﬂuence patient survival. 
More data are required on patients with large numbers of AAH to better 
understand the signiﬁcance in this group and determine clinical follow-
up strategy in AAH patients. 
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Background: 5-y surv in surgically resected St I NSCLC is 60-70% 
whereas in cases with affected lymph nodes (LN) it is < 50%. The main 
risk factor for recurrence is nodal disease. Current histopathologic 
analysis can miss occult micrometastases in nodal tissues at initial diag-
nosis. Detection of micromets with a more sensitive technique would 
be useful to deﬁne a high-risk population selecting patients (p) for po-
stop treatment. We assessed the role of several genes mRNA expression 
in pathological negative LN from resected St I NSCLC p as markers of 
occult micromets and correlated the results with relapse, and survival.
Methods: Paired tumor and histological negative LN (n=344) obtained 
by systematic mediastinal lymphadenectomy from 38 surgically 
resected St I NSCLC p were analyzed for the presence of 12 genes 
mRNA expression using RT-Q-PCR in an ABIPRISM 7500. RNA was 
extracted using ABIPRISM 6100. Speciﬁcally designed primers and 
probes were purchased from Applied Biosystems as Assay-on-demand; 
GADPH was used as an endogenous control. Samples were also ana-
lyzed by ICH for LN staging.
Results: 38 NSCLC p; 12 adenoca, 16 squamous cell, 10 undifferenti-
ated . From the 12 tested genes CEA and PLUNC were found with high 
expression in lung tissue and low or null expression in normal LN. We 
consider molecular + LN those in which expression of CEA or PLUNC 
was detected. In the 344 pathological negative LN, 13% (44/344) were 
positive for CEA, 16% (54/344) for PLUNC. The expression patterns 
were similar for both markers. At a median follow-up of 24 mo (9-46) 
11 p had died from NSCLC and 1 had died without recurrence. None 
of the living p had tumor recurrence. For the prognostic assessment, 
molecular + LN were classiﬁed as N1 and N2. Median DFS was 15 ± 
11.74 mo in p with N2 molecular + nodes and has not yet reached in 
cases of molecular (-) LN (p=0.028). Median survival of p with N2 
molecular positive nodes was 17.3 ± 5.7 mo and has not yet reached 
(p= 0.0083) for molecular (-) LN.
Conclusions: CEA and PLUNC mRNA expression could be used as 
molecular markers of occult micrometastases in mediastinal LN show-
ing a prognostic effect . CEA and PLUNC expression provides a tool 
for selecting high-risk p considered for adjuvant therapies
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Background: Akt (protein kinase B) is a key intracellular serine-threo-
nine kinase for transmission of cell survival (anti-apoptotic) signals. 
Activation of growth factor receptors results in phosphorylation and 
activation of Akt at S473 and T308. Multiple downstream survival sig-
nals are subsequently activated, which include among others fork-head 
transcription factor (FKHR), mTOR, Bad, and NFkB. PTEN inacti-
vates pAkt. Growth factor signaling is an important component in the 
progression of NSCLC, and clinical data suggest that it may be crucial 
for maintenance of the malignant phenotype in a subset of patients, 
particularly in adenocarcinomas, women, and those with a minimal 
smoking history. In addition, small and early-stage tumor may be more 
dependent on growth factor signaling than advanced and large tumors.
Methods: We used a novel, immunoﬂuorescence-based in situ protein 
detection method (AQUA) which allows for accurate, quantitative, and 
automated measurement of proteins in FFPE specimens in subcellular 
compartments. A tissue microarray that included 187 specimens from 
patients with completely resected stage I NSCLC that were not treated 
with (neo)adjuvant chemotherapy or radiation was constructed. After 
optimization of staining techniques, these specimens were evaluated for 
pAktS473, pAktT308, pFKHR, and PTEN expression, and results were 
analyzed for associations with clinicopathological parameters. Because 
of multiple comparison analysis, only associations with p-values =/< 
0.01 were considered interesting.
Results: There was a signiﬁcant positive correlation between 
pAkt(S473) and pFKHR expression (p<0.0001), and between 
pAkt(S473) and pAkt substrate expression (p<0.01). There was no 
association between pAkt(S473) and pAkt(T308) expression. PTEN 
and pAkt(T308) expression were inversely correlated (p<0.01), and 
PTEN and pAkt(S473) expression were positively correlated (p<0.01). 
Neither pAkt(S473) nor pAkt(T308) expression was signiﬁcantly as-
sociated with tumor histology (Kuskal Wallis test), gender (t-test), or 
smoking status. There was a signiﬁcant inverse correlation between 
tumor size and pAkt(T308) expression (p=0.001), which was not 
observed for pAkt(S473). Survival was better for patients with high cy-
toplasmic pAkt(S473) expression compared to low expression (p=0.02; 
HR=0.53; dichotomized by sample median), and for those with high 
nuclear pAkt(T308) (p=0.03; HR=0.56).
Conclusions: There is evidence for activity and clinical signiﬁcance of 
the Akt pathway in patients with early-stage NSCLC by AQUA analy-
sis of FFPE tumor specimens.
